BlossomHill is a pre-revenue biotech where insiders bought $25.2M (4.532% of market cap) while the shares sit in capitulation-style selling and the latest quarterly loss far exceeded estimates.
Thesis pillars
- Binary Biotech Risk→Stable
- Heavy Insider Buying↓Deteriorating
- Widening Quarterly Loss→Stable
- +1 more pillar — see the Why tab for full reasoning
BlossomHill Therapeutics, Inc. (BLSM) Stock Analysis
Oversold Bounce setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.94: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell... Read more
Sell if holding. Engine safety override at $13.94: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 19, near Bollinger lower, volume surge. Score 5.1/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 28d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-19Recent Developments — BlossomHill Therapeutics, Inc.
Latest news
- NEWS BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Fil — benzinga Sep 28, 2026 positive
- NEWS Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40 — benzinga Sep 21, 2026 positive
- NEWS Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40 — benzinga Sep 21, 2026 positive
- NEWS Earnings Scheduled For September 18, 2026 — benzinga Sep 18, 2026 neutral
- NEWS BlossomHill Therapeutics Q2 EPS $(8.75) — benzinga Sep 18, 2026 negative
Generated 2026-10-19T11:47:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.94: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 19, near Bollinger lower, volume surge. Prior stop was $12.96. Score 5.1/10, moderate confidence.
Analyst target: $30.80 (+120.9% upside). Prior stop was $12.96. Stop-loss: $12.96.
Quality below floor (2.9 < 4.0); Value-trap signals (2/5): Margin compression (op margin -39.6%), Material insider selling (22 sells, 1.00% of cap).
BlossomHill Therapeutics, Inc. trades at a P/E of N/A (forward -3.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
What does BlossomHill Therapeutics, Inc. do?BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that...
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.